Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 1
2002 1
2003 1
2004 1
2005 2
2006 3
2007 6
2008 2
2009 5
2010 3
2011 1
2013 3
2014 4
2015 4
2016 7
2017 2
2018 2
2020 4
2021 2
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Small molecule targeting of chromatin writers in cancer.
Conery AR, Rocnik JL, Trojer P. Conery AR, et al. Among authors: trojer p. Nat Chem Biol. 2022 Feb;18(2):124-133. doi: 10.1038/s41589-021-00920-5. Epub 2021 Dec 24. Nat Chem Biol. 2022. PMID: 34952934 Review.
Chromatin in the nuclear landscape.
Beck DB, Bonasio R, Kaneko S, Li G, Li G, Margueron R, Oda H, Sarma K, Sims RJ 3rd, Son J, Trojer P, Reinberg D. Beck DB, et al. Among authors: trojer p. Cold Spring Harb Symp Quant Biol. 2010;75:11-22. doi: 10.1101/sqb.2010.75.052. Epub 2011 Apr 18. Cold Spring Harb Symp Quant Biol. 2010. PMID: 21502408 Free PMC article. Review.
Targeting histone lysine methylation in cancer.
McGrath J, Trojer P. McGrath J, et al. Among authors: trojer p. Pharmacol Ther. 2015 Jun;150:1-22. doi: 10.1016/j.pharmthera.2015.01.002. Epub 2015 Jan 9. Pharmacol Ther. 2015. PMID: 25578037 Review.
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R, Colak G, Trojer P, Abramson JS. Blum KA, et al. Among authors: trojer p. Cancer Res Commun. 2022 Aug 11;2(8):795-805. doi: 10.1158/2767-9764.CRC-22-0060. eCollection 2022 Aug. Cancer Res Commun. 2022. PMID: 36923307 Free PMC article. Clinical Trial.
The key to development: interpreting the histone code?
Margueron R, Trojer P, Reinberg D. Margueron R, et al. Among authors: trojer p. Curr Opin Genet Dev. 2005 Apr;15(2):163-76. doi: 10.1016/j.gde.2005.01.005. Curr Opin Genet Dev. 2005. PMID: 15797199 Review.
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
Gehling VS, McGrath JP, Duplessis M, Khanna A, Brucelle F, Vaswani RG, Côté A, Stuckey J, Watson V, Cummings RT, Balasubramanian S, Iyer P, Sawant P, Good AC, Albrecht BK, Harmange JC, Audia JE, Bellon SF, Trojer P, Levell JR. Gehling VS, et al. Among authors: trojer p. ACS Med Chem Lett. 2020 May 6;11(6):1213-1220. doi: 10.1021/acsmedchemlett.0c00060. eCollection 2020 Jun 11. ACS Med Chem Lett. 2020. PMID: 32551003 Free PMC article.
Identification of potent, selective KDM5 inhibitors.
Gehling VS, Bellon SF, Harmange JC, LeBlanc Y, Poy F, Odate S, Buker S, Lan F, Arora S, Williamson KE, Sandy P, Cummings RT, Bailey CM, Bergeron L, Mao W, Gustafson A, Liu Y, VanderPorten E, Audia JE, Trojer P, Albrecht BK. Gehling VS, et al. Among authors: trojer p. Bioorg Med Chem Lett. 2016 Sep 1;26(17):4350-4. doi: 10.1016/j.bmcl.2016.07.026. Epub 2016 Jul 19. Bioorg Med Chem Lett. 2016. PMID: 27476424
57 results